• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Comparative Pathology >Isocitrate Dehydrogenase 1 Expression in Canine Gliomas
【24h】

Isocitrate Dehydrogenase 1 Expression in Canine Gliomas

机译：异柠檬酸脱氢酶1在犬胶质瘤中的表达

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Mutation of the isocitrate dehydrogenase 1 (IDH1) gene at codon 132 has been identified in approximately 70% of low-grade (II and III) human gliomas and secondary glioblastomas, with the IDH1 R132H point mutation representing 92.7% of these mutations. In people, the presence of an IDH1 gene mutation is associated with a better prognosis (both progression-free survival time and overall survival time) and a better response to therapy, including chemotherapy and radiation therapy. Furthermore, IDH1 mutations are included in diagnostic panels to improve diagnosis and molecular classification. Canine gliomas resemble their human counterpart both morphologically and immunohistochemically, therefore they are likely to share similar genetic abnormalities. The IDH1 gene is also comparable between man and dogs. If the IDH1 R132H point mutation is demonstrated in canine gliomas, the prognostic significance of this mutation in people may be transferable to the dog. The objective of this study was to investigate canine gliomas for the IDH1 R132H point mutation using immunohistochemistry. Thirty-one formalin-fixed and paraffin wax-embedded canine gliomas were examined for both IDH1 R132H expression and pan-IDH1 (IDH1 wild-type and point mutated IDH1). Glial tumour specimens were recorded to be either positive or negative for expression. Pan-IDH1 expression was identified in all 31 tumours (100%), while the IDH1 R132H point mutation was identified in none of the tumours (0%). Therefore, the IDH1 R132H point mutation was not identified in this population of canine gliomas and may not be a suitable biomarker or treatment target in canine gliomas. Further investigation is required to determine if other point mutations occur in the IDH1 gene of canine gliomas. (C) 2018 Elsevier Ltd. All rights reserved.
机译：在密码子132处的异亚硝酸脱氢酶1（IDH1）基因的突变已被鉴定为大约70％的低级（II和III）人胶质瘤和次生胶质细胞瘤，其IDH1 R132H点突变表示为这些突变的92.7％。在人的情况下，IDH1基因突变的存在与更好的预后（无进展生存时间和总生存时间）相关，以及对治疗的更好反应，包括化疗和放射治疗。此外，IDH1突变包括在诊断面板中以改善诊断和分子分类。犬胶质瘤类似于他们的人类对应，其在形态学和免疫组织化学，因此它们可能享有类似的遗传异常。人和狗之间的IDH1基因也是可比的。如果IDH1 R132H点突变在甘氨酸胶质瘤中证明，人们在人们中的预后意义可能可转移到狗身上。本研究的目的是使用免疫组化研究IDH1 R132H点突变的犬胶质瘤。针对IDH1 R132H表达和PAN-IDH1（IDH1野生型和点突变IDH1）检查三十一体福尔马林固定和石蜡嵌入的犬胶质瘤。胶质肿瘤标本被记录为表达的正面或阴性。在所有31个肿瘤（100％）中鉴定了泛IDH1表达，而IDH1 R132H点突变在肿瘤中没有鉴定（0％）。因此，在该犬胶质瘤的这种群体中未鉴定IDH1 R132H点突变，并且可能不是犬胶质瘤中的合适生物标志物或治疗靶标。需要进一步调查来确定其他点突变是否发生在犬胶质瘤的IDH1基因中。 （c）2018年elestvier有限公司保留所有权利。

著录项

  • 来源
    《Journal of Comparative Pathology》 |2018年第2018期|共7页
  • 作者

    Fraser A. R.; Bacci B.; le Chevoir M. A.; Long S. N.;

  • 作者单位

    Univ Melbourne Translat Res &

    Anim Clin Trial Studies Grp Sect Vet Neurol &

    Neurosurg 250 Princes Hwy Werribee Vic Australia;

    Univ Melbourne Dept Anat Pathol Fac Vet &

    Agr Sci 250 Princes Hwy Werribee Vic Australia;

    Univ Melbourne Translat Res &

    Anim Clin Trial Studies Grp Sect Vet Neurol &

    Neurosurg 250 Princes Hwy Werribee Vic Australia;

    Univ Melbourne Translat Res &

    Anim Clin Trial Studies Grp Sect Vet Neurol &

    Neurosurg 250 Princes Hwy Werribee Vic Australia;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 病理学;
  • 关键词

    dog; gene mutation; glioma; isocitrate dehydrogenase 1;

    机译：狗;基因突变;胶质瘤;异柠檬酸脱氢酶1;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号